News|Videos|July 10, 2026

Highlighting zuranolone's real-world effectiveness on postpartum depression with Joy Baker, MD

Author(s)Joy Baker, MD, OBGYN, FACOG, PMH-C, C-EFM, MT(ASCP)

Fact checked by: Joshua Fitch, Senior Editor , Nicole Canfora Lupo

The phase 4 study's oversampling of moderate PPD patients, showing a nearly 9-point EPDS drop by day 15, helps close a gap left by trials that enrolled predominantly severe cases.

A phase 4, prospective, real-world study of zuranolone (Zurzuvae; Sage Therapeutics and Biogen) for postpartum depression (PPD) produced clinically meaningful symptom improvement across all baseline severities, findings that coauthor Joy Baker, MD, FACOG, PMH-C, C-EFM, MT(ASCP), said should increase clinician comfort in prescribing the oral treatment beyond severe disease.^1,2